(Q35879455)

10 August 2017

Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9 (English)

1 reference

10 August 2017

1 reference

Javier Chaparro-Riggers

1

1 reference

10 August 2017

Hong Liang

2

1 reference

10 August 2017

Rachel M DeVay

3

1 reference

10 August 2017

Lanfang Bai

4

1 reference

10 August 2017

Janette E Sutton

5

1 reference

10 August 2017

Wei Chen

6

1 reference

10 August 2017

Tao Geng

7

1 reference

10 August 2017

Kevin Lindquist

8

1 reference

10 August 2017

Meritxell Galindo Casas

9

1 reference

10 August 2017

Leila M Boustany

10

1 reference

10 August 2017

Colleen L Brown

11

1 reference

10 August 2017

Jeffrey Chabot

12

1 reference

10 August 2017

Bruce Gomes

13

1 reference

10 August 2017

Pamela Garzone

14

1 reference

10 August 2017

Andrea Rossi

15

1 reference

10 August 2017

Pavel Strop

16

1 reference

10 August 2017

Dave Shelton

17

1 reference

10 August 2017

Jaume Pons

18

1 reference

10 August 2017

Arvind Rajpal

19

1 reference

10 August 2017

language of work or name

English

0 references

publication date

31 January 2012

1 reference

Journal of Biological Chemistry

10 August 2017

1 reference

10 August 2017

287

1 reference

10 August 2017

14

1 reference

10 August 2017

11090-11097

1 reference

describes a project that uses

10 August 2017

ImageJ

1 reference

11 June 2022

https://www.ebi.ac.uk/europepmc/webservices/rest/PMC3322827/fullTextXML

inferred from PubMed Central ID database lookup

cites work

Proprotein convertase substilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322827

A combinatorial histidine scanning library approach to engineer highly pH-dependent protein switches

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322827

A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322827

Strategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322827

Population pharmacokinetics of therapeutic monoclonal antibodies

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322827

Development trends for human monoclonal antibody therapeutics

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322827

A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322827

Enhanced antibody half-life improves in vivo activity

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322827

Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322827

A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322827

PCSK9: a convertase that coordinates LDL catabolism

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322827

Structural and biochemical characterization of the wild type PCSK9-EGF(AB) complex and natural familial hypercholesterolemia mutants

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322827

Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322827

Molecular basis of PCSK9 function

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322827

The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322827

The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322827

A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322827

Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322827

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322827

Engineered antibody Fc variants with enhanced effector function

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322827

Elimination mechanisms of therapeutic monoclonal antibodies

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322827

A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322827

Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322827

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322827

Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322827

The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322827

Rational cytokine design for increased lifetime and enhanced potency using pH-activated "histidine switching".

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322827

pH-dependent receptor/ligand dissociation as a determining factor for intracellular sorting of ligands for epidermal growth factor receptors in rat hepatocytes

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322827

Analysis of the pH dependence of the neonatal Fc receptor/immunoglobulin G interaction using antibody and receptor variants.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322827

The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs

24 September 2018

1 reference

12 December 2020

Antibodies as carrier proteins

1 reference

12 December 2020

Monoclonal antibody pharmacokinetics and pharmacodynamics

1 reference

12 December 2020

Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates

1 reference

12 December 2020

Identifiers

DOI

10.1074/JBC.M111.319764

1 reference

10 August 2017

1 reference

10 August 2017

PubMed publication ID

22294692

1 reference